Entero Healthcare Solutions Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹1,910Cr
- +42.6% YoY
- +11.9% QoQ
- Net profit
- ₹45Cr
- +45.2% YoY
- +32.4% QoQ
- Margin
- 4.5%
- +0.9 pp YoY
- +0.5 pp QoQ
Guidance rank: #9 of 30 in Retailing
See the sector's top 10 — free with your mobile number.
The short version
Entero Healthcare Solutions Limited targets consolidated revenue growth of 23% year-on-year for FY '27, excluding any new acquisitions. Revenue growth guidance for FY '27 is approximately 23%, combining ~11% calendarization impact and ~12% organic growth.
From Entero Healthcare Solutions Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Entero Healthcare Solutions Limited targets consolidated revenue growth of 23% year-on-year for FY '27, excluding any new acquisitions.
- Organic growth is expected to contribute significantly, with pharma and MedTech segments both equally driving growth.
- The company anticipates gross margin expansion, driven by scale and playing a full commercial role in certain product lines.
- They expect calendarization impacts of around 11% in revenue growth.
- Outperformance versus industry growth is targeted at around 1.4x to 1.5x the Indian Pharmaceutical Market (IPM) growth rate.
- The focus will be on profitable revenue growth, operational efficiencies, and higher-margin businesses while rationalizing low-margin segments.
2 more points from Entero Healthcare Solutions Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Entero Healthcare Solutions Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Focus is on consolidating and optimizing existing acquisitions rather than pursuing new ones.
- Company aims to spend more time organically building and optimizing the business platform rather than chasing new acquisition targets.
- Investment in working capital is largely in place as of Q4 FY26; incremental working capital needs will not be significant unless growth exceeds the guided 23%.
2 more points from Entero Healthcare Solutions Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Retailing
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Entero Healthcare Solutions Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Entero Healthcare Solutions Ltd said on order book & pipeline — free account, 30 seconds.
Entero Healthcare Solutions Ltd — Quarterly revenue & net profit
Entero Healthcare Solutions Ltd Q4 FY26 results — key figures
| ₹ Cr | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 1,910 | 1,339 | +42.6% | 1,707 | +11.9% |
| Operating profit (EBITDA) | 86 | 49 | +75.5% | 68 | +26.5% |
| Operating margin | 4.5% | 3.6% | +0.9 pp | 4% | +0.5 pp |
| Profit before tax | 58 | 37 | +56.8% | 40 | +45% |
| Net profit (PAT) | 45 | 31 | +45.2% | 34 | +32.4% |
| EPS (₹) | 6.44 | 5.90 | +9.2% | 6.35 | +1.4% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹2.1K Cr, net profit ₹61 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Entero Healthcar's management said in earlier quarters
Others in Retailing this season
- Intrasoft Technologies (Q4 FY26)
Revenue from operations for the quarter ended Mar-26: ₹13,604.74 lakhs . Key investor presentation takeaways from Intrasoft Technologies's Q4 FY26 investor pres
- Brand Concepts (Q4 FY26)
Q4 FY26 Revenue from Operations: INR 90.42 Cr., up 25.0% YoY (Page 11) . Key investor presentation takeaways from Brand Concepts Ltd's Q4 FY26 investor presenta
- Womancart (Q4 FY26)
Revenue for H2FY26: ₹8,388.9 Lakhs, up 125.8% YoY (Page 10, 8) . Key investor presentation takeaways from Womancart's Q4 FY26 investor presentation — and how it
- Avenue Supermarts (Q4 FY26)
FY22: ₹30,353 Cr . Key investor presentation takeaways from Avenue Supermarts's Q4 FY26 investor presentation — and how it ranks against sector peers.
Potential multibaggers · Q2 FY27
Potential multibaggers in Retailing
on management's own guidance
- Strong growth2
- Strong growth1
- Lenskart SolutionsGood growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Entero Healthcare Solutions Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Entero Healthcare Solutions Ltd Q4 FY26 results?
Entero Healthcare Solutions Limited targets consolidated revenue growth of 23% year-on-year for FY '27, excluding any new acquisitions. Revenue growth guidance for FY '27 is approximately 23%, combining ~11% calendarization impact and ~12% organic growth.
What is Entero Healthcare Solutions Ltd share price analysis?
Entero Healthcare Solutions Ltd currently shows a neutral. The stock trades at a P/E of 46.3 with a market cap of ₹5,479 Cr. Investors should review the full earnings analysis for detailed insights.
Is Entero Healthcare Solutions Ltd planning capital expenditure?
Focus is on consolidating and optimizing existing acquisitions rather than pursuing new ones.
Keep Entero Healthcare Solutions Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
